Characterization of Chemically Induced Ovarian Carcinomas in an Ethanol-Preferring Rat Model: Influence of Long-Term Melatonin Treatment

Luiz Gustavo A. Chuffa1,*, Beatriz A. Fioruci-Fontanelli1,2, Leonardo O. Mendes1,2, Wagner J. Fávaro3, Patricia Fernanda F. Pinheiro1, Marcelo Martinez4, Francisco Eduardo Martinez1

1 Departamento de Anatomia, Instituto de Biocicências, UNESP – Universidade Estadual Paulista, Botucatu-SP, Brazil, 2 Programa de Pós-Graduação em Biologia Celular e Estrutural, Instituto de Biologia, Universidade Estadual de Campinas – UNICAMP, Campinas-SP, Brazil, 3 Departamento de Anatomia, Biologia Celular e Fisiologia e Biofísica, UNICAMP – Universidade de Campinas, Campinas-SP, Brazil, 4 Departamento de Morfologia e Patologia, UFSCar – Universidade Federal de São Carlos, São Carlos-SP, Brazil

Abstract

Ovarian cancer is the fourth most common cause of cancer deaths among women, and chronic alcoholism may exert co-carcinogenic effects. Because melatonin (mel) has oncostatic properties, we aimed to investigate and characterize the chemical induction of ovarian tumors in a model of ethanol-prefering rats and to verify the influence of mel treatment on the overall features of these tumors. After rats were selected to receive ethanol (EtOH), they were surgically injected with 100 μg of 7,12-dimethyl-benz[a]anthracene (DMBA) plus sesame oil directly under the left ovarian bursa. At 260 days old, half of the animals received i.p. injections of 200 μg mel/100 g b.w. for 60 days. Four experimental groups were established: Group C, rats bearing ovarian carcinomas (OC); Group C+EtOH, rats voluntarily consuming 10% (v/v) EtOH and bearing OC; Group C+M, rats bearing OC and receiving mel; and Group C+EtOH+M, rats with OC consuming EtOH and receiving mel. Estrous cycle and nutritional parameters were evaluated, and anatomopathological analyses of the ovarian tumors were conducted. The incidence of ovarian tumors was higher in EtOH drinking animals 120 days post-DMBA administration, and mel efficiently reduced the prevalence of some aggressive tumors. Although mel promoted high EtOH consumption, it was effective in synchronizing the estrous cycle and reducing ovarian tumor mass by 20%. While rats in the C group displayed cysts containing serous fluid, C+EtOH rats showed solid tumor masses. After mel treatment, the ovaries of these rats presented as soft and mobile tissues. EtOH consumption increased the incidence of serous papillary carcinomas and sarcomas but not clear cell carcinomas. In contrast, mel reduced the incidence of sarcomas, endometrioid carcinomas and cystic teratomas. Combination of DMBA with EtOH intake potentiated the incidence of OC with malignant histologic subtypes. We concluded that mel reduces ovarian masses and the incidence of adenocarcinomas in ethanol-deprived rats.

Introduction

OC is the most lethal of all of the gynecological malignances [1]. The high incidence of OC has been attributed to primordial factors that are associated with ovarian senescence, such as oocyte depletion, low levels of steroid production, and increased levels of circulating gonadotropins [2]. OC has been presumed to arise from precursor lesions involving the ovarian surface epithelium (OSE) or ovarian epithelial inclusion cysts, which exhibit morphological features of the reproductive tract epithelium (or Mullerian aspects). Mullerian inclusion cysts may develop from the tubal epithelia by exfoliation or tubal-ovarian adhesions, during ovulation repair, or may even develop from endometrial cells via endometriosis [3–5]. Furthermore, several events associated with ovulation are hypothesized to be linked to OC initiation and progression, including proliferation of the OSE to repair ovulation-induced wounds on the ovarian surface [6], which may result in DNA damage; elevation of gonadotropin levels, stimulating the growth of the OSE [7]; and ovulation-induced inflammation, leading to the generation of reactive oxygen species (ROS) [8]. Approximately 90% of OCs are believed to arise from the OSE, while the remainder of ovarian neoplasms seem to be closely split between stromal and germ cell origins [9,10]. The lack of an adequate screening method to detect the early stages of the disease and its progression to chemoresistance has prevented appreciable improvements in the survival rate of patients suffering from OC.

Unfortunately, a paucity of OSE tumor animal models exist that can be extrapolated to tumors occurring in women. 7,12-dimethylbenz[a]anthracene (DMBA) is a well-known polycyclic aromatic carcinogen that is capable of inducing the initiation, promotion and progression of tumors [11]. After an optimal period of ovarian instillation, the observed neoplasms develop into massive tumors and occasionally evolve to intraperitoneal nodules.
Materials and Methods

Ovarian Tumor Induction Procedure

After being selected to consume ethanol, all of the animals (n = 80) were anesthetized with ketamine (50 mg/kg) and xylazine (10 mg/kg) prior to decapitation so that they were rendered unconscious. At 320 days of age, euthanasia was performed in accordance with the Canadian Council on Animal Experimentation. The present experimental protocol was previously accepted by the Ethical Committee of the Institute of Bioscience/UNESP (CEEA – Comité de Ética em Experimentação Animal), Campus of Botucatu, SP, Brazil (Permit Number: 382).
vehicle only. Antibiotic (10^5 units of benzylpenicillin potassium) was administered i.p. for the prophylactic treatment of infections before the abdominal wall was closed.

Mel Administration Procedure

Mel (M-5250, Sigma-Aldrich Chemical Co., St. Louis, MO, USA) was dissolved in 0.04 mL of 95% ethanol and diluted in 0.3 mL of 0.9% NaCl (vehicle) at a steady-state concentration of 0.3 mg/mL. The mixture was then injected i.p. in a total volume of 3.4 mL/kg of BW. All of the treated and untreated animals were injected with a vehicle solution. For the melatonin treatments, i.p. injections at doses of 200 μg/100 g of BW were administered daily for 60 days [27] in the evening (between 18:30–19:00 hours, at ZT 13, as shown in Fig. 1B).

Evaluation of Estrous Cycle and Nutritional Parameters

During the post-induction period, estrous cycles were monitored daily [at 9 a.m.] using a vaginal swab technique [28]. Fresh samples were transferred to clean slides and examined under an optical microscope. In addition, body weight gains, food consumption, and water/ethanol intake were measured every day at 9 a.m. for a period of each five days. After the melatonin treatment period, all of the rats were monitored by vaginal swabbing in a dark room using red dim illumination for subsequent euthanasia (anesthesia followed by decapitation) during the early morning at 4 a.m. (or Zeitgeber Time (ZT) 22, corresponding to the environmental circadian time, as shown in Fig. 1B).

Determination of Plasma Mel Concentrations

After blood collection [at 4 a.m.], mel was extracted from the plasma [n = 10 samples/group] using HPLC grade methanol and was then separated on columns [Sep-Pak Vac C-18, reverse phase, 12.5 nm] (Water Corporation, Milford, Massachusetts, USA). Thereafter, 50 μL of reconstituted samples were assayed using a Coat-a-count Melatonin ELISA Kit and measured at 405 nm. The intra-assay coefficient of variation was 4%. All of the samples were assayed in duplicate at the same time to avoid inter-assay variability. All of the reagents and microtiter plates were provided by IBL (IBL International, Hamburg, Germany). The concentrations of melatonin are reported as pg/mL.

Ovarian Histology Analyses

After euthanasia, all of the animals were necropsied and examined for abnormalities. Pathologically altered organs, female reproductive tracts, and organs/tissues related to body metabolism (liver, kidneys, pancreas, intestines, lymph nodes, and spleen) were removed during necropsy. In rats with evident ovarian tumors, specimens were also excised and frozen in liquid nitrogen, followed by storage at −80°C. For the histological analyses, the ovaries were fixed in 10% (v/v) buffered formalin (for 24 h), transferred to 70% ethanol, dehydrated, and paraffin embedded. Sections that were 5-μm thick were generated, and every 20th section was stained with hematoxylin and eosin (H&E). Histopathological analyses were conducted by a pathologist with expertise in animal malignancies. The ovarian tumors were subtyped according to the histological aspects of the neoplasms.

Statistical Analysis

The values are presented as the means ± standard deviation (SD). The data analyses were performed using two-way ANOVA (analysis of variance) for two independent factors (ethanol consumption and mel treatment). Significant results were subjected to post-hoc testing using Tukey’s test, and statistical significance was set at p<0.05. GraphPad Instat Version 4 statistical software and Sigma Plot Version 11.0 graphing software were used in this study.

Results

Nutritional Parameter and Estrous Cycle Examinations

During the experimental period, all of the animals were monitored and handled based on the same criteria. The amount of food intake and energy intake (derived from the feed and ethanol) did not differ between the experimental groups (p>0.05). However, the animals in Group C, independent of mel treatment, consumed more water than those in Group C+EtOH, regardless of treatment. Ethanol consumption was unaltered after ovarian tumor induction. When mel was administered, the amount of ethanol consumed increased after the first week through the end of the treatment period (34% increase in Group C+EtOH+M as compared to Group C+EtOH, as shown in Table 1).

After tumor induction, the estrous cycles of rats in both Groups C and C+EtOH were longer (25% and 30.3% increase compared to Groups C+M and C+EtOH+M, respectively), and displayed transitional phase irregularities, particularly prolongation in the diestrus phase (50% of the analyzed period). Notably, mel was effective in reducing both the duration of the estrous phase and the extension of the diestrus phase. The disturbances in the estrous phase did not differ statistically between the groups (Table 2).
Levels of Ovarian Tumors and Plasma Melatonin

Incidence of Ovarian Tumors and Plasma Melatonin

The values are expressed as the means ± SD. N = 20/group.

| Parameters | Vehicle | Vehicle+Melatonin |
|------------|---------|-------------------|
|            | C+EtOH  | C                 |
| Food Consumption | 15.31 ± 0.46  | 14.80 ± 0.65  |
| Energy Intake (food+ethanol) | 47.83 ± 1.17  | 49.59 ± 1.26  |
| Relative Water Intake | 7.36 ± 0.35  | 12.89 ± 0.22*  |
| Relative Ethanol Intake (PT) | 4.86 ± 0.37  | 0.00  |
| Relative Ethanol Intake (AT) | 5.16 ± 0.89  | 0.00  |

The sham-operated ovaries (*) appeared to be intact with no macroscopic lesion.

Histological Features of Ovarian Tumors

The majority of ovarian tumors were adenocarcinomas. After 180 days of ovarian tumor induction, the experimental groups displayed variations in the histotypes and grades of the tumors. Serous papillary carcinomas were more prevalent in animals from the C+EtOH (24/80) and C+EtOH+M (22/70) groups than in the C (10/60) and C+M (6/50) groups. Conversely, clear cell carcinomas were predominant in animals from the C (5/60) and C+M (4/50) groups compared to the animals in the C+EtOH (4/80) and C+EtOH+M (4/70) groups. Sarcomas were more prevalent in animals from the C (3/60) and C+EtOH (5/80) groups, and mel therapy was thought to have reduced their appearance (2/50 in Group C+M and 2/70 in Group C+EtOH+M). There was a low prevalence of undifferentiated carcinomas in Groups C (1/60), C+EtOH (1/80) and C+EtOH+M (1/70), and undifferentiated carcinomas were absent in Group C+M. Squamous cell carcinomas were present only in the groups that consumed ethanol, whether they had received mel (2/80 in Group C+EtOH and 2/70 in Group C+EtOH+M). Only Groups C (1/60) and C+EtOH (2/80) developed endometrioid carcinomas and mature cystic teratomas, respectively. Benign ovarian tumors were identified in Groups C (3/60) and C+M (5/60).
and were more prevalent in the latter group (Table 4). No tumors with histological characteristics resembling either granulosa cell or germ cell tumors were observed. The most different types of ovarian carcinomas that were common in the four experimental groups are illustrated in Figures 4 and 5.

### Discussion

The present study is the first to demonstrate an association between DMBA and 10% (v/v) ethanol intake during ovarian tumor development, as well as the long-term effects of mel treatment on the general aspects of the tumors. The evidence supporting the effects of ethanol on DMBA-induced tumors in a classic model of UCchB rats include the observations that: (a) ethanol increased the cumulative incidence of ovarian tumors (post-DMBA injection), (b) the weights and sizes of the tumors were increased after ethanol consumption, and (c) more tumors had malignant characteristics in the ethanol consumption group. Many studies have indicated that ethanol acts as a co-carcinogenic agent in several diseases [29–31]. Epidemiological studies reported that a direct correlation between ethanol consumption and the increased risk for developing ovarian cancer is dependent upon the amount and exposure time (chronic or more acute exposure), and that the effects of ethanol on ovarian tumorigenesis seem to be caused primarily by hormonal disturbances [15,32]. We have already mentioned the most deleterious effects of chronic ethanol intake on the ovaries, such as alterations in estrogen- and progesterone-receptors (ER-alpha, ER-beta, PRA and PRB), increases in estradiol levels, high ROS production, and changes in the ovarian structure and ultra-structure [27,33,34]. Furthermore, ethanol and its metabolite, acetaldehyde, are capable of inducing DNA adduct formation and cytochrome P450-mediated ROS generation, while also depleting folate levels [29,35,36].

### Table 3. Final body weights (g), body weight gains (%), ovarian sizes (mm), and absolute (g) and relative (g/100 g B.W) reproductive tissue weights in the four experimental groups.

| Parameters                  | Groups               | C+EtOH       | C            | C+EtOH+M    | C+M         |
|-----------------------------|----------------------|--------------|--------------|-------------|-------------|
| Final Body Weight           |                      | 255 ± 4.36   | 252 ± 3.59   | 258 ± 3.73  | 250 ± 4.10  |
| Body Weight Gain            |                      | 28 ± 0.4     | 26 ± 0.6     | 29 ± 0.4    | 25 ± 0.8    |
| Left Ovarian Weight*        |                      | 0.24 ± 0.04  | 0.22 ± 0.01  | 0.19 ± 0.02a| 0.17 ± 0.02b|
| Relative Weight of the Left Ovary* |              | 0.09 ± 0.01  | 0.09 ± 0.01  | 0.07 ± 0.01a| 0.06 ± 0.01b|
| Left Ovarian Size*          |                      | 15.9 ± 3.7   | 20.0 ± 4.2   | 12.8 ± 2.5a | 16.4 ± 3.7b|
| Right Ovarian Weight        |                      | 0.048 ± 0.00 | 0.056 ± 0.00a| 0.059 ± 0.01a| 0.051 ± 0.01a|
| Relative Weight of the Right Ovary |              | 0.02 ± 0.00  | 0.02 ± 0.00  | 0.03 ± 0.00  | 0.02 ± 0.00  |
| Oviduct Weight              |                      | 0.031 ± 0.02 | 0.033 ± 0.03 | 0.029 ± 0.01 | 0.030 ± 0.01 |
| Relative Weight of the Oviducts |              | 0.012 ± 0.01 | 0.013 ± 0.01 | 0.012 ± 0.03 | 0.013 ± 0.01 |
| Uterine Weight              |                      | 0.50 ± 0.16  | 0.53 ± 0.13  | 0.48 ± 0.15  | 0.52 ± 0.11  |
| Relative Weight of the Uterus |              | 0.15 ± 0.04  | 0.16 ± 0.06  | 0.18 ± 0.09  | 0.18 ± 0.08  |

The values are expressed as the means ± SD. N = 20/group. a, b, c P < 0.05 versus Groups C+EtOH, C and C+EtOH+M, respectively. (*) indicates that the left ovary was chemically induced with DMBA. Two-way ANOVA followed by Tukey’s test.

doi:10.1371/journal.pone.0081676.t003

Figure 2. Period of tumor development and plasma melatonin levels during the treatment. Cumulative incidence (%) of ovarian tumors from 80 to 180 days post-DMBA injection (A). From 120 to 180 days post-DMBA induction, the ovaries of the animals in Group C+EtOH showed a significant incidence of tumor development. *P<0.05 vs. Group C. (B) Detection of plasma melatonin levels prior to treatment initiation (day 0) and after 30- and 60- days of treatment. *P<0.05 vs. Groups C and C+EtOH, respectively. **P<0.05 vs. 30 days of treatment in the same group.

doi:10.1371/journal.pone.0081676.g002
Figure 3. Photographs of the most common ovarian tumors 180 days post-DMBA induction. (A and C) The left ovary (arrowhead) of an animal from the C-EtOH group showing a solid mass with scattered necrosis. (B) The left ovary (arrowhead) of an animal from Group C, displaying a...
developing tumors, ethanol-prefering rats can be an excellent option for enhancing tumor development in the presence of an active carcinogen (e.g., DMBA).

In contrast, we report that mel treatment significantly improved the general aspects of ovarian tumors. Although mel administration produces alcohol cravings, but not food-seeking behavior, it can reduce both relative and absolute ovarian tumor weights and sizes without affecting body weight. We know that OC risk is strongly linked to an increased number of lifetime ovulations. Thus, a blockage of incessant ovulation using oral contraceptives, or even pregnancy, may protect the ovaries from OC [37]. In the present study, DMBA administration alone, or in combination

Figure 4. Photomicrographs of the three most prevalent intraovarian DMBA-induced ovarian tumors in UChB rats. In Group C, serous borderline tumors displayed an exophytic papillary architecture (A and B) mixed with extensive micropapillae formation, or tufts back-to-back (C). The majority of these adenocarcinomas exhibited invasive gland-like neoplastic structures invading the cortex. The C+EtOH (D), C+M (E) and C+EtOH+M (F) groups presented very complex micropapillary patterns, composed of columnar atypical cells, with no stromal invasion. Clear cell carcinosomas (asterisk) with solid growths surrounding the stromal tissues were observed in Groups C (G), C+EtOH (H), C+M (I) and C+EtOH+M (J). Sarcoma cells (asterisk) were arranged in bundles and streams with spindle shapes and occupied extramedullary sites in Groups C (K), C+EtOH (L), C+M (M) and C+EtOH+M (N). Sham-operated right ovaries with developing and mature follicles and new corpora lutea in Groups C (O), C+EtOH (P), C+M (Q) and C+EtOH+M (R). Original low magnification, bar = 200 μm; H&E stain.

doi:10.1371/journal.pone.0081676.g004
Figure 5. Histologic subtypes of ovarian tumors in the four experimental groups. In Group C: A) Serous carcinoma characterized by papillae formation with cellular budding (arrows), bar = 20 μm. B) Clear cell carcinoma composed of numerous vacuolated cells, bar = 20 μm. C) Ovarian carcinoma in situ. The epithelium is composed of stratified cells with loss of nuclear polarity and nuclear pleomorphism with chromatin clumping (arrowhead), bar = 20 μm. D) Sarcoma composed of non-epithelial malignant cells, bar = 20 μm. In Group C+M: E) Serous carcinoma with a
pattern of papillae, bar = 50 μm. F) Serous papillary cystadenoma (borderline tumor) showing a higher complexity of cellular stratification, bar = 20 μm. G) Pattern of clear cell carcinoma with hobnail cells, bar = 20 μm. H) Sarcoma, bar = 20 μm. In Group C+EtOH: I) Serous carcinoma showing a section of a papillae (arrow), bar = 20 μm. J) Squamous carcinoma composed of squamous epithelial cells (asterisk), bar = 50 μm. K) Mature cystic teratoma with malignant content were scattered in the ovarian stroma (white arrows), bar = 50 μm. L) Clear cell carcinoma, bar = 20 μm. M) Sarcoma, bar = 20 μm. In Group C+EtOH+M, serous carcinoma showing a cross-section of a papillae (N), bar = 20 μm. O) Squamous carcinoma, bar = 50 μm. P) Ovarian carcinoma with the presence of specifically undifferentiated cells (asterisk). The stroma displayed a marked infiltration of inflammatory cells (arrow), bar = 20 μm. Q) Sarcoma, bar = 20 μm; H&E stain.

In the present study, we determined the ovarian tumor subtype based on histological observations. Spontaneous development of epithelial cancers is rarer in rodent ovaries [43] than in the ovaries of human beings. One plausible explanation for the low incidence is the fact that the rat ovaries are surrounded by a membranous pouch, which provides natural protection against the local effects of carcinogens [46]. To date, most of the studies of DMBA-induced tumors in rodent species (rat or mice) have generated reproducible ovarian neoplasms using various simulation methods and routes of carcinogen administration [11,26,47,48], including gavage, coated suture or local instillation, dosage, time of drug delivery, and appropriate time for tumor development and growth. Interestingly, 120 days post-DMBA induction, the incidence of ovarian tumors was significantly increased after ethanol consumption (60% in the controls vs. 74% in the EtOH-treated group), of which 48% were adenocarcinomas of surface epithelial origin. Therefore, the development of neoplasms in DMBA-treated rats that had undergone ovarian failure (constant ethanol exposure) demonstrates an elevated susceptibility to develop ovarian tumors. However, the exact mechanism(s) involved in this ovarian sensitivity require further investigation. Although ethanol has the ability to act systematically on the whole body, all of the ovarian tumors were originated from the surface epithelium or cysts. It is believed that tumor origin may be related more to disruptions of the OSE than to perturbations of follicular or stromal tissues. Some of the DMBA-induced lesions, especially those related to the surface epithelium, were similar to the isolated papillae or diffuse papillomatosis found in human OC. Additionally, other OSE-derived structures that are commonly described in humans (i.e., simple microcysts or serous cysts) were eventually observed in the rat ovaries. In the present study, the development of the putative precursor lesions associated with DMBA exhibited degrees of differentiation and progression (i.e., cellular atypia and dysplasia) varying from low- to high-grade malignant potential. Briefly, clear cell carcinomas and sarcomas displayed similar features to those that occur in women. Several studies have shown a stronger relationship between DMBA-induced OC and human OC, both at the morphological and molecular levels [48–50]. Although DMBA is not a known environmental carcinogen that is linked to OC, it may share mutagenic mechanisms with other polycyclic aromatic compounds that are present at high concentrations in air pollutants or in tobacco, both of which have been implicated to play roles in human cancer development.

Further strengthening our findings, plasma mel concentrations were significantly elevated in the animals from both the C+M and C+EtOH+M groups, which ensured that an effective long-term therapy schedule had been followed. Although ethanol intake had been described to inhibit plasma mel [51], it was not sufficient to alter the continuous availability of mel in the early morning during the treatment period. Additionally, the nocturnal peaks of mel appeared to exacerbate both locomotor activity and EtOH-seeking behavior, while no apparent influence on the daytime behavior of the animals was observed. A notable activity rhythm after the administration of exogenous mel is typically found in nocturnal species (e.g., rodents) [52].

Table 4. Prevalence (%) of the different ovarian tumor subtypes, observed 180 days after DMBA injection in the four experimental groups.

| Histologic Types          | Groups  | C        | C+M     | C+EtOH | C+EtOH+M |
|---------------------------|---------|----------|---------|--------|----------|
| Serous Papillary          |         | 16.6%    | 12.05%  | 30.00% | 31.33%   |
| Clear Cell Carcinoma      |         | 8.50%    | 7.63%   | 5.11%  | 5.95%    |
| Sarcoma                   |         | 5.00%    | 3.84%   | 6.25%  | 2.85%    |
| Undifferentiated          |         | 1.65%    | –       | 1.25%  | 1.43%    |
| Carcinoma                 |         |          |         | 2.50%  | 2.86%    |
| Squamous Cell             |         |          |         |        |          |
| Carcinoma                 |         |          |         |        |          |
| Endometrioid              |         | 1.66%    | –       | –      | –        |
| Carcinoma                 |         |          |         |        |          |
| Mature Cystic             |         |          |         | 2.50%  | –        |
| Teratoma                  |         |          |         |        |          |
| Benign Ovarian Tumor      |         | 5.02%    | 10.07%  | –      | –        |

N = 20/group.

Table: 10.1371/journal.pone.0081676.t004
In regard to advanced ovarian tumors, melatonin alone reduced the incidence of serous papillary carcinomas, while the combination of DMBA with ethanol increased their appearance, regardless of mel treatment. This may be attributed to the effects of ethanol more than to the effects of DMBA itself. Conversely, a low incidence of clear cell carcinomas was observed after DMBA plus ethanol intake, and mel did not seem to affect this tumor subtype. In both ethanol-consuming and control animals, a low incidence of sarcomas was observed following melatonin treatment. Undifferentiated carcinomas had a very low incidence, and mel treatment alone suppressed its development. Intriguingly, only the combination of DMBA and ethanol intake led to the development of squamous cell carcinomas, and mel did not affect these tumors. There was also a low incidence of endometrioid carcinomas and mature cystic teratomas in the DMBA- and DMBA-ethanol treated groups, respectively. A high incidence of benign ovarian tumors was observed in DMBA-treated rats, and mel treatment further increased the incidence. In this group, mel may have exerted a beneficial effect, as evidenced by the reduced incidence of malignant ovarian tumors.

Notably, no inhibitory effects of melatonin (1 and 100 nM) on the growth of ovarian cancer cells in culture medium enriched with 1 nM 17β-estradiol were observed in in vitro studies [53]. Taking into account the fact that various experimental conditions were modified, such as differing melatonin incubation times (from 48 to 144 h) with stimulatory repetition every 24 h, or the use of different culture media, the effects of melatonin may be undetectable due to these variations. In addition, in vitro studies using different doses of mel (50, 100 and 200 nM) are being conducted on primary OC cultures originating from UCB rats (preliminary data not shown).

Ovarian Cancer & Ethanol: Benefits of Melatonin

Alterating the progression of DMBA-initiated cells to the formation of a tumor is an incessant paradigm in the chemoprevention area. Studies conducted by our research group examining chemoprevention and chemoresistance to drugs using this rat model are currently underway to assess the effectiveness of melatonin in stimulating immune function and inhibiting ovarian tumorigenesis.

In summary, chronic ethanol consumption enhanced the incidence of ovarian carcinomas in the presence of intraovarian DMBA. Furthermore, the association of DMBA with ethanol intake caused an increase in ovarian tumor mass with a high prevalence of malignant histologic subtypes. Although mel treatment promoted significant increases in ethanol consumption, it was able to effectively reduce ovarian mass. In addition to these benefits, mel also reduced the incidence of ovarian adenocarcinomas in ethanol-deprived rats. These data represent an important benchmark for understanding ovarian cancer development in a model of ethanol-prefering rats, and also suggest that melatonin may potentially be used as adjuvant therapy.

Acknowledgments

We are grateful to Mr Thiago da Silva and Mr. Geison Rodriguez from Department of Anatomy, IBB/UNESP, Botucatu-SP, for excellent technical support.

Author Contributions

Conceived and designed the experiments: LGAC FEM. Performed the experiments: LGAC PFFP LOM BAFF FEM. Wrote the paper: LGAC FEM WJP.

References

1. Stakleff KD, Von Gruenigen VE (2003) Rodent models for ovarian cancer research. Int J Gynecol Cancer 13: 405–412.
2. Vanderhyden BC (2005) Loss of ovarian function and the risk of ovarian cancer. Cell Tiss Res 322: 117–124.
3. Chien JR, Aletti G, Bell DA, Keeny GL, Shridhar V, et al. (2007) Molecular pathways and therapeutic targets in epithelial ovarian cancer. J Cell Biochem 102: 1117–1129.
4. Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, et al. (2007) Lessons from BRCa: the tubal fimbra emerges as an origin for pelvic serous cancer. Clin Med Res 5: 35–44.
5. Fleming JS, Beaugie CR, Havil I, Chevnevis-Trench G, Tan OL (2006) Incessant ovulation, inflammation and epithelial ovarian carcinogenesis revisiting old hypotheses. Mol Cell Endocrinol 247: 4–21.
6. Fathalla MF (1971) Incessant ovulation- a factor in ovarian neoplasia? Lancet 2: 163.
7. Konishi I, Kuroda H, Mandai M (1999) Review: gonadotropins and the incidence of ovarian carcinomas in rat. Acta Obstet Gynecol Jpn 38: 570–574.
8. Hoyer PB, Davis JR, Bedrnicek JB, Marion SL, Christian PJ (2009) Ovarian ethanol preference: UChA and UChB strains. Neurobehav Toxicol Teratol 5: 127–128.
9. La Vecchia C, Negri E, Franceschi S, Parazzini F, Gentile A, et al. (1992) Alcohol and epithelial ovarian cancer. J Clin Epidemiol 45: 1025–1030.
10. Rota M, Pasquali E, Scotti L, Pelucchi C, Tramacere I, et al. (2012) Alcohol drinking and epithelial ovarian cancer risk: a systematic review and meta-analysis. Gynecol Oncol 125: 758–763.
11. Traverger SS, Gergar DM, Gates MA, Hecht JL, Hankinson SE (2008) Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer. Cancer 112: 1169–1177.
12. Marldones J, Segovia-Riquelme N (1983) Thirty-two years of selection of rats by ethanol preference: UChA and UChB strains. Neurobehav Toxicol Teratol 5: 127–128.
13. Asa FS, Gómez A, Marínez-Campa C, Mediavilla MD, Alonso-González C, et al. (2008) Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Targets 8: 691–702.
14. Reiter RJ (2004) Mechanisms of cancer inhibition by melatonin. J Pineal Res 38: 213–214.
15. Conne A, Maestrini GM (1995) The clinical neuroimmunotherapeutic role of melatonin in oncology. J Pineal Res 19: 103–110.
16. Sada S, Ramesh R, Mhashkar AM (2003) Cytokine- and chemokine-based gene therapy for cancer. Curr Opin Mol Ther 5: 463–474.
17. Sauer LA, Dauchy RT, Blask DE (2001) Polyunsaturated fatty acids, melatonin and cancer progression. Biochem Pharmacol 61: 1453–1462.
18. Hoyer PB, Davis JR, Bedrnicek JB, Marion SL, Christian PJ (2009) Ovarian neoplasm development by 7,12-dimethylbenza[a]anthracene (DMBA) in a chemically-induced rat model of ovarian failure. Gynecol Oncol 112: 610–615.
19. Chuffa LG, Amorim JP, Teixeira GR, Mendes LO, Forucia BA, et al. (2011a) Long-term exogenous melatonin treatment modulates overall liver efficiency and protects ovarian tissue against injuries caused by ethanol-induced oxidative stress in adult UCB rats. Alcohol Clin Exp Res 35: 1498–1508.
20. Chuffa LG, Seiva FR, Favaro WJ, Teixeira GR, Amorim JP, et al. (2011b) Melatonin reduces LH, 17 beta-estradiol and induces differential regulation of sex steroid receptors in reproductive tissues during rat ovulation. Reprod Biol Endocrinol 9: 108.
29. Berstad P, Ma H, Bernstein L, Ursin G (2008) Alcohol intake and breast cancer risk among young women. Breast Cancer Res Treat 108: 113–120.
30. Jacinto-Alemán LF, García-Carranca A, Leyba-Huerta ER, Zenteno-Galindo L, Jiménez-Farías MD, et al. (2013) erbB expression changes in ethanol and 7,12-dimethylbenz[a]anthracene-induced oral carcinogenesis. Med Oral Patol Oral Cir Bucal 18: e325–e331.
31. Seitz HK, Wang XD (2013) The role of cytochrome P450 2E1 in ethanol-mediated carcinogenesis. Subcell Biochem 67: 131–145.
32. Schouten LJ, Zeeegri MP, Godboleh RA, Van Den Brandt PA (2004) Alcohol and ovarian cancer risk results from the Netherlands Cohort Study. Cancer Causes Control 15: 201–209.
33. Chuffa LG, Padovani CR, Martínez FE (2009) Ovarian structure and hormonal status of the UChA and UChB adult rats in response to ethanol. Maturitas 62: 21–29.
34. Chuffa LG, Seiva FR, Fávaro WJ, Amorim JP, Teixeira GR, et al. (2013) Melatonin and ethanol intake exert opposite effects on circulating estradiol and progesterone and differentially regulate sex steroid receptors in the ovaries, oviducts, and uteri of adult rats. Reprod Toxicol 39: 40–49.
35. Wang Y, Millionig G, Nair J, Patsenker E, Stickel F, et al. (2009) Ethanol-induced cytochrome P-4502E1 causes carcinogenic etheno-DNA lesions in alcoholic liver disease. Hepatology 50: 453–461.
36. Poschl G, Seitz HK (2004) Alcohol and cancer. Alcohol Alcohol 39: 155–165.
37. King SM, Hilliard TS, Wu LY, Jaffe RC, Fazleabas AT, et al. (2011) The impact of ovulation on fallopian tube epithelial cells: evaluating three hypotheses connecting ovulation and serous ovarian cancer. Endocr Relat Cancer 18, 627–642.
38. Crespi F (2012) Influence of melatonin or its antagonism on alcohol consumption in ethanol drinking rats: a behavioral and in vivo volumetric study. Brain Res 1542: 39–46.
39. Srinivasan V, Pandi-Perumal SR, Brzezinski A, Bhatnagar KP, Cardinali DP (2011) Melatonin, immune function and cancer. Recent Pat Endocr Metab Immune Drug Discov 5: 109–123.
40. Lissoney P (2007) Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol Biol 55: 201–204.
41. Molpeceres V, Maurici JL, García-Mediavilla MV, González P, Barrio JP, et al. (2007) Melatonin is able to reduce the apoptotic liver changes induced by aging via inhibition of the intrinsic pathway of apoptosis. J Gerontol A Biol Sci Med Sci 62: 687–693.
42. Xi SC, Siu SW, Fong SW, Fong SW, Shiu SY (2001) Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression. Prostate 46: 52–61.
43. Prata Lima MF, Barata RC, Simões MJ (2004) Effects of melatonin on the ovarian response to pinealectomy or continuous light in female rats: similarity with polycystic ovary syndrome. Braz J Med Biol Res 37: 987–995.
44. Chuffa LG, Amorim JP, Teixeira GR, Mendes LO, Fioruci BA, et al. (2011) Long-term melatonin treatment reduces ovarian mass and enhances tissue antioxidant defenses during ovulation in the rat. Braz J Med Biol Res 44: 217–223.
45. Godvin AK, Testa JR, Handel LM, Lau Z, Vanderveer LA, et al. (1992) Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst 84: 592–601.
46. Chien JR, Aletti G, Bell DA, Keeney GL, Shridhar V, et al. (2007) Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. J Cell Biochem 102: 1117–1129.
47. Huang Y, Jiang W, Wang Y, Zheng Y, Cong Q, et al. (2012) Enhanced efficacy and specificity of epithelial ovarian carcinogenesis by embedding a DMBA-coated cloth strip in the ovary of rats. J Ovarian Res 5: 21.
48. Crist KA, Zhang Z, You M, Gunning WT, Couran PB, et al. (2005) Characterization of rat ovarian adenocarcinomas developed in response to direct instillation of 7,12-dimethylbenz[a]anthracene (DMBA) coated suture. Carcinogenesis 26: 951–957.
49. Stewart SL, Quevec TD, Ochman AR, Guerrier BN, Bao R, et al. (2004) Characterization of a carcinogenesis rat model of ovarian preneoplasia and neoplasia. Cancer Res 64, 8177–8183.
50. Vanderhyden BC, Shaw TJ, Ethier JF (2003) Animal models of ovarian cancer. Reprod Biol Endocrinol 1: 67.
51. Pérez R, do Amaral FG, Madrigrano TC, Scialla JH, Bordin S, et al. (2011) Ethanol consumption and pineal melatonin daily profile in rats. Addict Biol 16: 580–590.
52. Fisher SP, Sugden D (2010) Endogenous melatonin is not obligatory for the regulation of the rat sleep-wake cycle. Sleep 33, 833–840.
53. Treeck O, Haldar C, Ortmann O (2006) Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines. Oncol rep 15: 231–235.